Brain-computer Interface System for Training Memory and Attention in Elderly With Subjective Memory Deficits and Age Related Cognitive Decline (ARCD)
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Study Overview
Brief Summary
The primary objective is to examine the efficacy of 8-weeks of a locally developed brain-computer interface based system intervention for improving attention and memory in healthy elderly and those with age related cognitive decline. We hypothesize that elderly who have completed the training program will have significant improvement in their attention and memory compared to the controls, based on the Repeatable Battery for the Assessment of Neuropsychological Status.
Detailed Description
The world population has reached an unprecedented seven billion, with global population ageing increasing at a greater rate than total population growth. Between 1998 and 2030, the proportion of persons aged 65 years and over in Singapore will grow by about 3% annually compared to 1.0-1.3% in some developed nations. Specific cognitive deficits like inattention, dysexecutive functioning, and processing speed decline may affect a number of quality of life domains. Concurrent with these statistics, the maintenance of the highest possible level of cognitive functioning for as long as possible has become an important goal of aging successfully.
To contribute to the realization of this goal we propose to conduct a wait-list control trial to examine the efficacy of this brain-computer interface based intervention for cognitive enhancement in elderly. This intervention uses a technology which analyzes brain waves captured through an electroencephalogram to determine the participants' state of attention. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
This intervention may represent one alternative means to enhance cognitive abilities and to slow down cognitive decline in the normal elderly. If demonstrated to be efficacious, this therapy may even help to delay the onset of dementia.
In addition, the rate of cognitive decline during the course of AD is possibly influenced by not only environmental but also genetic factors. To date, several genes, such as apolipoprotein E (APOE) and TOMM40 (translocase of outer mitochondrial membrane 40 homologue), have been identified to be probable genetic risk markers for AD. These genes have been shown to play a role in disease onset as well as rates of cognitive decline. For instance, studies have shown APOEε4 allele carriers to be associated with earlier and faster cognitive decline.
Therefore, we propose to analyse if there is any relationship between the genetic profiles of our participants and their performance in the training program.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 60 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Age 60-80 years old
- •Clinical Dementia Rating (CDR) of 0-0.5
- •Mini Mental State Examination (MMSE) of 24 and above
- •Geriatric Depression Scale (GDS) of 4 and below
- •Chinese Ethnicity
- •Literate in English
- •Able to travel to study site independently
Exclusion Criteria
- •Any known neuropsychiatric disorders (such as epilepsy or mental retardation)
- •Involvement in another research study (aside from the Singapore Longitudinal Ageing Study)
- •Gross hearing, visual or speech impairment that are uncorrected
- •Color Blindness
- •Intake of the following medications: Rivastigmine, Donepezil, Galantamine or Memantine.
Arms & Interventions
BCI Intervention
Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
Intervention: Brain-Computer Interface (Device)
Waitlist Control Group
The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
Outcomes
Primary Outcomes
Total Score of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Time Frame: Comparison in the change of RBANS total score from pre-treatment (Week 0) to post-treatment (Week 9) in Intervention Group versus Waitlist-Control group
The Total Score on RBANS reflects the neurocognitive status of the participant by summing five index/domain scores. The domains are Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory.
Secondary Outcomes
- Number of Adverse Events/Serious Adverse Events Reported(Throughout the intervention period (Up to 20 weeks) for both groups)
- Usability Measure of the Brain-Computer Interface training system(At the end of the 8 weeks of treatment for both groups (Week 20 for the Intervention group, Week 29 for the Waitlist-Control group))
- Sum of Scaled Score of the Rivermead Behavioral Memory Test-II(Comparison in the change of RBMT-2 sum of scale score from pre-treatment (Week 0) to post-treatment (Week 9) in Intervention Group versus Waitlist-Control group)
Investigators
Lee Tih Shih
Associate Professor
Duke-NUS Graduate Medical School